Offer to Purchase for Cash All Outstanding Shares of Common Stock ofGalenica AG • August 4th, 2016 • Pharmaceutical preparations
Purchaser hereby offers to purchase any and all outstanding Shares of Relypsa, net to the seller thereof in cash, without interest and less any applicable withholding taxes, on the terms and subject to the conditions set forth in this Offer to Purchase and in the related Letter of Transmittal.
RELYPSA, INC.Galenica AG • August 4th, 2016 • Pharmaceutical preparations • New York
FORM OF SUPPORT AGREEMENTSupport Agreement • October 29th, 2007 • Galenica AG • Pharmaceutical preparations • British Columbia
This Agreement sets out the terms and conditions of the agreement of the Aspreva Shareholder to take certain actions and to do certain things, including to vote or cause to be voted the Aspreva Common Shares and Aspreva Options, if any, owned by the Aspreva Shareholder, and the Aspreva Common Shares over which the Aspreva Shareholder has control or direction, in favour of the Arrangement Resolution approving the Arrangement.
AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENT BETWEEN RELYPSA, INC. AND GALENICA LTD.Confidentiality Agreement • August 4th, 2016 • Galenica AG • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE CONFIDENTIALITY AGREEMENT (“Amendment No. 1”) is made and entered into effective as of May 11, 2016 (the “Amendment No. 1 Effective Date”) by and between RELYPSA, INC., a Delaware corporation, located at 100 Cardinal Way, Redwood City, CA 94063 (“Relypsa”) and Galenica Ltd., with an address at Untermattweg 8, 3027 Bern, Switzerland (“Recipient”).
AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENT BETWEEN RELYPSA, INC. AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.Confidentiality Agreement • August 4th, 2016 • Galenica AG • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE CONFIDENTIALITY AGREEMENT (“Amendment No. 1”) is made and entered into effective as of May 6, 2015 (the “Amendment No. 1 Effective Date”) by and between RELYPSA, INC., a Delaware corporation, located at 100 Cardinal Way, Redwood City, California 94063 (“Relypsa”) and VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD., Rechenstrasse 37, 9001 St. Gallen, Switzerland (“Vifor”).
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • August 4th, 2016 • Galenica AG • Pharmaceutical preparations
THIS CONFIDENTIALITY AGREEMENT (hereinafter referred to as the “Agreement”) shall be effective as of the 6th day of May, 2014 (hereinafter referred to as the “Effective Date”) and is entered into by and between
JOINT FILING AGREEMENTJoint Filing Agreement • May 22nd, 2017 • Vifor Pharma Ltd. • Pharmaceutical preparations
This Joint Filing Agreement, dated as of May 22, 2017, is made by and between Vifor (International) Ltd., an entity formed under the laws of Switzerland, and Vifor Pharma Ltd., an entity formed under the laws of Switzerland. The foregoing are collectively referred to herein as the “Parties” and each individually as a “Party.” Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the Parties hereby acknowledge and agree that the Schedule 13D is filed on behalf of each such Party and that all subsequent amendments to the Statement on Schedule 13D shall be filed on behalf of each of the Parties without the necessity of filing additional joint acquisition statements. The Parties hereby acknowledge that each Party shall be responsible for timely filing of such amendments, and for the completeness and accuracy of the information concerning such Party contained therein, but shall not be responsible for the completeness and accuracy of the informa
JOINT FILING AGREEMENTJoint Filing Agreement • October 29th, 2007 • Galenica AG • Pharmaceutical preparations
This JOINT FILING AGREEMENT, dated as of October 29, 2007, is made by and between Galenica Canada Ltd., a corporation existing under the laws of the Province of British Columbia, Canada ("Galenica Canada"), and Galenica AG, a corporation existing under the laws of Switzerland ("Galenica"). Galenica Canada and Galenica are collectively referred to herein as the "Parties" and each individually as a "Party." Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the Parties hereby acknowledge and agree that the Schedule 13D is filed on behalf of each such Party and that all subsequent amendments to the Statement on Schedule 13D shall be filed on behalf of each of the Parties without the necessity of filing additional joint acquisition statements. The Parties hereby acknowledge that each Party shall be responsible for timely filing of such amendments, and for the completeness and accuracy of the information concerning such Party contained there
